← Back to Clinical Trials
Recruiting NCT06567977

NCT06567977 TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06567977
Status Recruiting
Phase
Sponsor Chiesi Poland Sp. z o.o.
Condition Asthma
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2024-08
Primary Completion 2025-03-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Trimbow

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2024-08 with a primary completion date of 2025-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes.

Eligibility Criteria

Inclusion Criteria: * Patients ≥ 18 years of age, * Patients with confirmed leading diagnosis of asthma with or without concomitant COPD, * Physician decision to start fixed triple therapy with ICS/LABA/LAMA (Trimbow® MS or HS) according to its current authorised indication. The treatment decision must be made independently from participation in this NIS, * Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study. Exclusion Criteria: • Participation in an interventional clinical trial within 30 days prior to en-rolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.

Contact & Investigator

Central Contact

Tomasz Debowski, Md Phd

✉ t.debowski@chiesi.com

📞 +48-800 506 122 982

Frequently Asked Questions

Who can join the NCT06567977 clinical trial?

This trial is open to participants of all sexes, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06567977 currently recruiting?

Yes, NCT06567977 is actively recruiting participants. Contact the research team at t.debowski@chiesi.com for enrollment information.

Where is the NCT06567977 trial being conducted?

This trial is being conducted at Tarnowskie Góry, Poland.

Who is sponsoring the NCT06567977 clinical trial?

NCT06567977 is sponsored by Chiesi Poland Sp. z o.o.. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology